San Francisco, CA
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)Scleroderma Research Foundation, founded in 1987, is a mid-sized nonprofit in the Medical Research sector that reported $13.1M in total revenue in fiscal year 2025. The organization ran a surplus of $2.8M, a strong 21% operating margin.
The mission of the Scleroderma Research Foundation is to fund and facilitate the most promising, highest quality research aimed at new treatments and, ultimately, a cure for scleroderma.
CONQUEST is a global, perpetual, clinical trial platform developed by the SRF in coordination with partner biopharmaceutical companies to accelerate the clinical development of agents for...
CONQUEST is a global, perpetual, clinical trial platform developed by the SRF in coordination with partner biopharmaceutical companies to accelerate the clinical development of agents for scleroderma. CONQUEST is designed to rapidly advance promising treatments for scleroderma and to identify those agents that should progress from phase 2b to phase 3 clinical trials. CONQUEST will make an enduring contribution to the scleroderma community by creating an ecosystem designed to enable rapid and efficient development of novel drugs for scleroderma patients.
The mission of the Scleroderma Research Foundation (SRF) is to find, fund, and facilitate the most promising, highest-quality research to cure scleroderma. We recruit the best and the brightest...
The mission of the Scleroderma Research Foundation (SRF) is to find, fund, and facilitate the most promising, highest-quality research to cure scleroderma. We recruit the best and the brightest researchers to understand the causes, discover treatments, and ultimately eradicate this disease . At the SRF, research is at the center of all we do. Our Research Program is governed by the Board of Directors and supported by a volunteer Scientific Advisory Board comprised of some of the world's most highly regarded scientists who are leaders in their field of expertise. The Board of Directors and Scientific Advisors meet annually with researchers and clinicians from laboratories across the nation to select and fund the most promising scleroderma studies aimed at developing improved therapies to help patients live longer, fuller lives - and, ultimately, to find a cure for scleroderma.
SRF Education & Awareness Program: Many patients hear the word scleroderma for the first time when they are diagnosed. We strive to raise awareness and provide educational resources because lack of...
SRF Education & Awareness Program: Many patients hear the word scleroderma for the first time when they are diagnosed. We strive to raise awareness and provide educational resources because lack of awareness about scleroderma often causes delays in treatment or misdiagnosis. As an innovator in scleroderma research, the SRF is uniquely qualified to provide those living with this disease, the medical community, and the general public with the most up-to-date, trusted and relevant news and information about complications, treatments, and related research through our website, webinars, annual patient forum, and monthly eNewsletter. And we deliver stories of impact that connect and inspire patients, as well as address issues related to diversity, equity, and inclusion that patients may encounter as they navigate diagnosis, treatment, and living with the disease.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2025 | 2024 | Change | |
|---|---|---|---|
| Revenue | $13,131,089 | $12,173,161 | +0.1% |
| Expenses | $10,325,525 | $9,622,521 | +0.1% |
| Net Income | $2,805,564 | $2,550,640 | +0.1% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| Gregory Gordon | Chief Medical Officer | 40.00 |
|
$526,440 | $935 | $527,375 |
| Joanne Gold | Executive Dir. | 40.00 |
Officer
|
$220,205 | $18,062 | $238,267 |
| Gloria Blecha | VP Communications | 40.00 |
|
$179,263 | $15,879 | $195,142 |
| Hannah Young | Dir. Communication | 40.00 |
|
$130,689 | $7,851 | $138,540 |
| Neha Pamboo | Sr. Acct. Manager | 40.00 |
|
$118,965 | $10,521 | $129,486 |
| Anoushka Donnelley | Dir. Philanthropy | 40.00 |
|
$112,854 | $7,656 | $120,510 |
| Luke Evnin PhD | Chairman | 40.00 |
Officer
Director
|
$0 | $0 | $0 |
| Susan Feniger | Secretary | 10.00 |
Officer
Director
|
$0 | $0 | $0 |
| Deann Wright | Treasurer | 10.00 |
Officer
Director
|
$0 | $0 | $0 |
| Omar Baker MD | Board Member | 2.00 |
Director
|
$0 | $0 | $0 |
| Sharon Dobie MD | Board Member | 2.00 |
Director
|
$0 | $0 | $0 |
| Eric Kau MD | Board Member | 2.00 |
Director
|
$0 | $0 | $0 |
| David Knoller | Board Member | 1.00 |
Director
|
$0 | $0 | $0 |
| Violetta Merin | Board Member | 1.00 |
Director
|
$0 | $0 | $0 |
| Mark Scher | Board Member | 1.00 |
Director
|
$0 | $0 | $0 |
| Regina Hall | Board Member | 1.00 |
Director
|
$0 | $0 | $0 |
| Jeff Seaman | Board Member | 2.00 |
Director
|
$0 | $0 | $0 |
| Dan Schimberg | Board Member | 2.00 |
Director
|
$0 | $0 | $0 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2025 | $13,131,089 | $10,325,525 | $42,239,970 | $2,805,564 |
| 2024 | $12,173,161 | $9,622,521 | $32,999,784 | $2,550,640 |
| 2023 | $8,418,038 | $6,487,599 | $18,654,748 | $1,930,439 |
| 2022 | $5,892,738 | $4,658,602 | $11,143,637 | $1,234,136 |
| 2021 | $3,768,969 | $3,687,303 | $9,819,469 | $81,666 |
| 2020 | $3,931,140 | $2,957,771 | $9,592,172 | $973,369 |
| 2019 | $5,168,122 | $3,364,239 | $7,445,548 | $1,803,883 |
| 2018 | $4,733,081 | $3,005,455 | $5,318,800 | $1,727,626 |
Compare Scleroderma Research Foundation with other nonprofits in California and across the country.